Protective efficacy of a SARS-CoV-2 DNA vaccine in wild-type and immunosuppressed Syrian hamsters

Abstract A worldwide effort to counter the COVID-19 pandemic has resulted in hundreds of candidate vaccines moving through various stages of research and development, including several vaccines in phase 1, 2 and 3 clinical trials. A relatively small number of these vaccines have been evaluated in SA...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Rebecca L. Brocato, Steven A. Kwilas, Robert K. Kim, Xiankun Zeng, Lucia M. Principe, Jeffrey M. Smith, Jay W. Hooper
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/021913bd329840d1928fea1d69b27f9e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:021913bd329840d1928fea1d69b27f9e
record_format	dspace
spelling	oai:doaj.org-article:021913bd329840d1928fea1d69b27f9e2021-12-02T14:16:48ZProtective efficacy of a SARS-CoV-2 DNA vaccine in wild-type and immunosuppressed Syrian hamsters10.1038/s41541-020-00279-z2059-0105https://doaj.org/article/021913bd329840d1928fea1d69b27f9e2021-01-01T00:00:00Zhttps://doi.org/10.1038/s41541-020-00279-zhttps://doaj.org/toc/2059-0105Abstract A worldwide effort to counter the COVID-19 pandemic has resulted in hundreds of candidate vaccines moving through various stages of research and development, including several vaccines in phase 1, 2 and 3 clinical trials. A relatively small number of these vaccines have been evaluated in SARS-CoV-2 disease models, and fewer in a severe disease model. Here, a SARS-CoV-2 DNA targeting the spike protein and delivered by jet injection, nCoV-S(JET), elicited neutralizing antibodies in hamsters and was protective in both wild-type and transiently immunosuppressed hamster models. This study highlights the DNA vaccine, nCoV-S(JET), we developed has a great potential to move to next stage of preclinical studies, and it also demonstrates that the transiently-immunosuppressed Syrian hamsters, which recapitulate severe and prolonged COVID-19 disease, can be used for preclinical evaluation of the protective efficacy of spike-based COVID-19 vaccines.Rebecca L. BrocatoSteven A. KwilasRobert K. KimXiankun ZengLucia M. PrincipeJeffrey M. SmithJay W. HooperNature PortfolioarticleImmunologic diseases. AllergyRC581-607Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Vaccines, Vol 6, Iss 1, Pp 1-7 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Rebecca L. Brocato Steven A. Kwilas Robert K. Kim Xiankun Zeng Lucia M. Principe Jeffrey M. Smith Jay W. Hooper Protective efficacy of a SARS-CoV-2 DNA vaccine in wild-type and immunosuppressed Syrian hamsters
description	Abstract A worldwide effort to counter the COVID-19 pandemic has resulted in hundreds of candidate vaccines moving through various stages of research and development, including several vaccines in phase 1, 2 and 3 clinical trials. A relatively small number of these vaccines have been evaluated in SARS-CoV-2 disease models, and fewer in a severe disease model. Here, a SARS-CoV-2 DNA targeting the spike protein and delivered by jet injection, nCoV-S(JET), elicited neutralizing antibodies in hamsters and was protective in both wild-type and transiently immunosuppressed hamster models. This study highlights the DNA vaccine, nCoV-S(JET), we developed has a great potential to move to next stage of preclinical studies, and it also demonstrates that the transiently-immunosuppressed Syrian hamsters, which recapitulate severe and prolonged COVID-19 disease, can be used for preclinical evaluation of the protective efficacy of spike-based COVID-19 vaccines.
format	article
author	Rebecca L. Brocato Steven A. Kwilas Robert K. Kim Xiankun Zeng Lucia M. Principe Jeffrey M. Smith Jay W. Hooper
author_facet	Rebecca L. Brocato Steven A. Kwilas Robert K. Kim Xiankun Zeng Lucia M. Principe Jeffrey M. Smith Jay W. Hooper
author_sort	Rebecca L. Brocato
title	Protective efficacy of a SARS-CoV-2 DNA vaccine in wild-type and immunosuppressed Syrian hamsters
title_short	Protective efficacy of a SARS-CoV-2 DNA vaccine in wild-type and immunosuppressed Syrian hamsters
title_full	Protective efficacy of a SARS-CoV-2 DNA vaccine in wild-type and immunosuppressed Syrian hamsters
title_fullStr	Protective efficacy of a SARS-CoV-2 DNA vaccine in wild-type and immunosuppressed Syrian hamsters
title_full_unstemmed	Protective efficacy of a SARS-CoV-2 DNA vaccine in wild-type and immunosuppressed Syrian hamsters
title_sort	protective efficacy of a sars-cov-2 dna vaccine in wild-type and immunosuppressed syrian hamsters
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/021913bd329840d1928fea1d69b27f9e
work_keys_str_mv	AT rebeccalbrocato protectiveefficacyofasarscov2dnavaccineinwildtypeandimmunosuppressedsyrianhamsters AT stevenakwilas protectiveefficacyofasarscov2dnavaccineinwildtypeandimmunosuppressedsyrianhamsters AT robertkkim protectiveefficacyofasarscov2dnavaccineinwildtypeandimmunosuppressedsyrianhamsters AT xiankunzeng protectiveefficacyofasarscov2dnavaccineinwildtypeandimmunosuppressedsyrianhamsters AT luciamprincipe protectiveefficacyofasarscov2dnavaccineinwildtypeandimmunosuppressedsyrianhamsters AT jeffreymsmith protectiveefficacyofasarscov2dnavaccineinwildtypeandimmunosuppressedsyrianhamsters AT jaywhooper protectiveefficacyofasarscov2dnavaccineinwildtypeandimmunosuppressedsyrianhamsters
_version_	1718391645316055040

Protective efficacy of a SARS-CoV-2 DNA vaccine in wild-type and immunosuppressed Syrian hamsters

Ejemplares similares